Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis

Area of Science:

• Neuroimmunology
• Pharmacology

Background:

• Dimethyl fumarate (DMF) is an established oral therapy for relapsing-remitting multiple sclerosis (RRMS).
• The precise molecular mechanisms underlying DMF's therapeutic effects remain under investigation.
• Emerging evidence suggests a role for both nuclear factor erythroid-derived 2-related factor (Nrf2)-dependent and independent pathways.

Purpose of the Study:

• To review the molecular and signaling effects of Dimethyl fumarate (DMF).
• To elucidate how DMF influences peripheral immune cell composition and function.
• To examine DMF's impact on central nervous system (CNS) cells and the blood-brain barrier.

Main Methods:

• Literature review of studies investigating DMF's mechanism of action.
• Analysis of molecular signaling pathways affected by DMF.
• Examination of effects on immune cell differentiation and function (e.g., Th2, myeloid cells).

Main Results:

• DMF induces an anti-inflammatory immune response.
• Key effects include differentiation of type II myeloid cells and Th2 cells.
• Neuroprotective effects and modulation of CNS cell functions are observed.
• DMF influences the integrity and function of the blood-brain barrier.

Conclusions:

• Dimethyl fumarate (DMF) exerts therapeutic effects in RRMS through complex immunomodulatory and neuroprotective mechanisms.
• Understanding these pathways, including Nrf2-dependent and independent actions, is crucial for optimizing treatment.
• DMF's impact extends to peripheral immunity, CNS cells, and the blood-brain barrier, highlighting its multifaceted role.